癌症药物在自闭症谱系障碍中重新使用
Giorgia Pedini1, Chin-Lin Chen2, Tilmann Achsel2
1University of Rome Tor Vergata, Department of Biomedicine and Prevention, Via Montpellier 1, 00133, Rome, Italy.
Trends in pharmacological sciences
|November 8, 2023
概括
重用癌症药物为自闭症谱系障碍 (ASD) 提供了一种新的治疗策略,通过准共享的分子途径. 这种方法解决了对ASD有效治疗的迫切需要,改善了患者的治疗结果.
科学领域:
- 神经科学是一个神经科学.
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 自闭症谱系障碍 (ASD) 是一种复杂的神经发育状况,对其机制的理解有限,缺乏有效的治疗方法.
- 自闭症的遗传多样性使传统药物开发复杂化,需要新的治疗策略.
- 自闭症诊断的发病率不断上升,强调了对创新干预措施的迫切需要.
研究的目的:
- 探索ASD和癌症之间的共同分子通路.
- 突出重新利用已有的癌症药物用于ASD治疗的潜力.
- 讨论在ASD中成功重新使用药物的关键考虑因素.
主要方法:
- 科学文献的审查,重点关注ASD和癌症常见的分子途径.
- 识别现有的癌症药物,在ASD中具有潜在的治疗应用.
- 分析影响重定向药物的有效性和安全性的因素.
主要成果:
- 共同的分子通路,包括mTOR信号传递,基因素脱乙酶活性和炎症过程,都与ASD和癌症有关.
- 特定类型的癌症药物,如mTOR抑制剂,胰岛素脱乙酶抑制剂和抗炎药物,显示出对ASD治疗的希望.
- 优化试验设计,考虑药物剂量,患者年龄,副作用和商业可行性对于成功重新定位至关重要.
结论:
- 重用癌症药物代表了开发新型ASD治疗的有希望的途径.
- 准共享的分子通路为ASD药物开发提供了合理的方法.
- 解决临床试验和药物开发管道中的实际挑战对于将这种潜力转化为有效的治疗方法至关重要.
相关概念视频
01:19Autism Spectrum Disorder
102
Autism spectrum disorder (ASD) is a neurodevelopmental condition marked by persistent deficits in social communication and interaction alongside restrictive and repetitive behaviors or interests. ASD is sometimes accompanied by intellectual impairment.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
These core symptoms manifest differently among individuals, ranging from mild to severe. The disorder's complexity extends beyond its clinical presentation, encompassing a diverse range of biological, cognitive, and sociocultural influences.
102
02:57Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
03:03mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K